SGA
JAZZ icon

Seaport Global Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Seaport Global Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,667
Closed -$734K – 78
2023
Q3 		$734K Buy
+5,667
New +$755K 2.2% 11
2022
Q1 		– Sell
-4,054
Closed -$516K – 113
2021
Q4 		$516K Buy
+4,054
New +$533K 0.7% 52

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Seaport Global Advisors's JAZZ Position: Q4 2023 in Review

Seaport Global Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 5,667 shares — an estimated $734K sold.

Seaport Global Advisors first reported a position in JAZZ in Q4 2021 and held it in 2 quarters. The position peaked at $734K in Q3 2023. 500 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

  • Seaport Global Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Seaport Global Advisors sold 5,667 Jazz Pharmaceuticals shares in Q4 2023, an estimated $734K.
  • Seaport Global Advisors first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Seaport Global Advisors's Jazz Pharmaceuticals position peaked at $734K in Q3 2023.
  • 500 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on Seaport Global Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.